Keryx Biopharmaceuticals Inc.
http://www.keryx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Keryx Biopharmaceuticals Inc.
Autobahn Speeds Lead Drug Into Phase II With $100m In Fresh Cash
Autobahn raised $100m in series C venture capital to take its oral, brain-penetrant thyromimetic ABX-002 into Phase II studies in major depressive disorder and bipolar disorder depression.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
BIO Chair Ted Love On Drug Pricing And Political Pressure
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Access Oncology
- AOI Pharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice